



Express Mail No.: **EV 654 850 418 US**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Srivastava

Confirmation No.: 9970

Application No.: 09/992,613

Group Art Unit: 1642

Filed: November 14, 2001

Examiner: YAEN, Christopher H.

For: IMMUNOTHERAPEUTIC STRESS  
PROTEIN-PEPTIDE COMPLEXES  
AGAINST CANCER

Attorney Docket No.: 8449-183-999

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §1.56 AND §1.97**

**MAIL STOP AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the U.S. Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application which are or may be material to the patentability of any claim of the application, Attorneys for Applicant respectfully direct the Examiner's attention to the references **ER** to **EX** listed on the attached List of References Cited by Applicant. Pursuant to the amendments to 37 C.F.R. § 1.98(s)(2) announced in the September 21, 2004 Federal Register, copies of U.S. patent and published U.S. patent applications are no longer required to be submitted in connection with the filing of an Information Disclosure Statement, regardless of the filing date of the subject application. *See* 69 Fed. Reg. 56482, 56510. Accordingly only copies of references **ES** to **EX** are submitted herewith.

Applicant respectfully requests that the Examiner review the listed references and that the references be made of record in the file history of the application. Identification of the listed references is not meant to be construed as an admission of Applicant or Attorneys for Applicant that such references are available as "prior art" against the subject application.

Applicant respectfully requests that the Examiner review the listed references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b), since it is believed that this information disclosure statement is being filed before the mailing date of the first Office Action on the merits, no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Jones Day Deposit Account No. 50-3013.

Respectfully submitted,

Date: June 24, 2005

Adriane M. Antler 32,605  
Adriane M. Antler (Reg. No.)

By: T. Christopher Tsang 40,258  
T. Christopher Tsang (Reg. No.)

**JONES DAY**  
222 East 41<sup>st</sup> Street  
New York, New York 10017  
(212) 326-3939

*Enclosures*

Express Mail No.: **EV 654 850 418 US**

Sheet 1 of 1

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

ATTY. DOCKET NO.

8449-183-999

APPLICATION NO.

09/992,613

APPLICANT

Srivastava

FILING DATE

November 14, 2001

GROUP

1642

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
ER	5,652,115	07/29/97	Marks <i>et al.</i>	435	7.23	

**FOREIGN PATENT DOCUMENTS**

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
					YES NO

**OTHER REFERENCES** (Including Author, Title, Date, Pertinent Pages, Etc.)

ES	Clarke, et al., 1988, "Purification of complexes of nuclear oncogene p53 with rat and Escherichia coli heat shock proteins: in vitro dissociation of hsc70 and dnaK from murine p53 by ATP," Mol. Cell Biol. 8(3):1206-1215
ET	Davidoff et al., 1992, "Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers," Proc. Natl. Acad. Sci. USA 89(8):3439-3442
EU	Halevy et al., 1990, "Different tumor-derived p53 mutants exhibit distinct biological activities," Science 250(4977):113-116
EV	Hinds et al., 1990, "Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes," Cell Growth Differ. 1(12):571-580
EW	Hinds et al., 1987, "Immunological evidence for the association of p53 with a heat shock protein, hsc70, in p53-plus-ras-transformed cell lines," Mol. Cell Biol. 7(8):2863-2869
EX	Pinhasi-Kimhi, 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock proteins," Nature 320(6058):182-184

**EXAMINER****DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.